ATE472998T1 - Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis - Google Patents

Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis

Info

Publication number
ATE472998T1
ATE472998T1 AT07725375T AT07725375T ATE472998T1 AT E472998 T1 ATE472998 T1 AT E472998T1 AT 07725375 T AT07725375 T AT 07725375T AT 07725375 T AT07725375 T AT 07725375T AT E472998 T1 ATE472998 T1 AT E472998T1
Authority
AT
Austria
Prior art keywords
treatment
rheumatoid arthritis
liposomal preparations
cationic liposomal
cationic
Prior art date
Application number
AT07725375T
Other languages
English (en)
Inventor
Martin Funk
Brita Schulze
Eric Guenzi
Uwe Michaelis
Hermann Bohnenkamp
Martin Eichhorn
Marcus Schmitt-Sody
Original Assignee
Medigene Ag
Univ Muenchen L Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Univ Muenchen L Maximilians filed Critical Medigene Ag
Application granted granted Critical
Publication of ATE472998T1 publication Critical patent/ATE472998T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07725375T 2006-05-18 2007-05-18 Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis ATE472998T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80107906P 2006-05-18 2006-05-18
US87932007P 2007-01-09 2007-01-09
PCT/EP2007/004467 WO2007134819A1 (en) 2006-05-18 2007-05-18 Cationic liposomal preparations for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ATE472998T1 true ATE472998T1 (de) 2010-07-15

Family

ID=38512671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07725375T ATE472998T1 (de) 2006-05-18 2007-05-18 Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis

Country Status (5)

Country Link
US (1) US20090232731A1 (de)
EP (1) EP2040674B1 (de)
AT (1) ATE472998T1 (de)
DE (1) DE602007007618D1 (de)
WO (1) WO2007134819A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052766A2 (en) * 2006-11-03 2008-05-08 Medigene Ag Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
ES2770575T3 (es) 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
EP2638896A1 (de) * 2012-03-14 2013-09-18 Bioneer A/S Kationisches liposomales Arzneimittelabgabesystem für spezifisches Targeting humaner CD14+ Monozyten in Vollblut
DK2854769T3 (da) 2012-07-05 2023-06-26 Taiwan Liposome Co Ltd Fremgangsmåder til behandling af artritis
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
EP3345614A1 (de) * 2017-01-05 2018-07-11 Amrif B.V. Zusammensetzung mit alkalinphosphatase zur verwendung bei der behandlung von arthritiden
EP3962533A4 (de) * 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. Plattform zur verabreichung durch das trommelfell und deren verwendungen
CN113616597A (zh) * 2021-08-02 2021-11-09 上海交通大学 一种美洛昔康的注射剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
JP2001527052A (ja) * 1997-12-23 2001-12-25 アイネックス ファーマシューティカルズ コーポレイション ポリアミドオリゴマー
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2001082899A2 (en) * 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
AU2003249882B2 (en) * 2002-06-26 2008-09-18 Medigene Ag Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1374864A1 (de) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphile, Taxane enthaltende Zusammensetzungen
EP2286794B8 (de) * 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Verwendung von kationischen liposomen mit paclitacel
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy

Also Published As

Publication number Publication date
EP2040674A1 (de) 2009-04-01
WO2007134819A1 (en) 2007-11-29
US20090232731A1 (en) 2009-09-17
DE602007007618D1 (de) 2010-08-19
EP2040674B1 (de) 2010-07-07

Similar Documents

Publication Publication Date Title
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201500156A2 (ru) Доставка антител посредством модульного домена распознавания
EA200970738A1 (ru) Ингибиторы активности akt
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2009003981A (es) Agentes moduladores del receptor de calcio.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties